These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9205748)

  • 1. Pharmacokinetics of ebrotidine in rats and dogs.
    Albet C; Pérez JA; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):483-5. PubMed ID: 9205748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ebrotidine in healthy volunteers. A summary.
    Albet C; Pérez JA; Rozman E; Márquez M; Herrero E; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):535-9. PubMed ID: 9205760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability and pharmacokinetics of ebrotidine in healthy subjects given single and repeated oral doses.
    Farré M; Roset PN; Badenas JM; Ugena B; Márquez M; Albet C; Herrero E; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):528-30. PubMed ID: 9205758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic study of ebrotidine administered in multiple doses to healthy volunteers for 4 days.
    Frías J; Esteban C; Carcas AJ; Sánchez-García P; Albet C; Torres J; Márquez M; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):531-4. PubMed ID: 9205759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
    Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute toxicity studies of ebrotidine.
    Grau MT; Romero A; Villamayor F; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):490-1. PubMed ID: 9205750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subacute toxicity of ebrotidine in rats and dogs.
    Romero A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):492-7. PubMed ID: 9205751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic toxicity of ebrotidine in rats and dogs.
    Romero A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):498-504. PubMed ID: 9205752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of plasma gastrin levels in rats after two months of ebrotidine administration.
    Romero A; Gómez F; Villamayor F; Ballesta A; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):524-7. PubMed ID: 9205757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study on the increment of the amount of gastric mucus in rats after repeated-dose administration of ebrotidine.
    Romero A; Villamayor F; Palop D; Falcó J; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):455-8. PubMed ID: 9205743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
    Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinogenicity studies on ebrotidine.
    Romero A; Rives A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):515-9. PubMed ID: 9205755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories.
    Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys.
    Maeshiba Y; Kiyota Y; Yamashita K; Yoshimura Y; Motohashi M; Tanayama S
    Arzneimittelforschung; 1997 Jan; 47(1):29-35. PubMed ID: 9037440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
    Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of famotidine in man.
    Kroemer H; Klotz U
    Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):458-63. PubMed ID: 2888738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of endogenous nitric oxide and sulfhydryl compounds in ebrotidine-induced gastroprotection.
    Palop D; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):468-71. PubMed ID: 9205745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of the safety and efficacy of ebrotidine versus ranitidine and placebo in the prevention of piroxicam-induced gastroduodenal lesions.
    Puscas I; Puscas C; Coltau M; Pasca R; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):568-72. PubMed ID: 9205767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the population of antral G-cells and enterochromaffin-like cells in the rat and mouse gastric mucosa after long-term treatment with ebrotidine.
    Romero A; Gómez F; Villamayor F; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):520-3. PubMed ID: 9205756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.